Wugen Presents New Preclinical Data from Novel Memory Natural Killer (NK) Platform at The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
— Wugen’s proprietary platform employs a GMP-grade, feeder cell-free manufacturing process to produce commercially scalable, off-the-shelf, non-engineered memory natural killer (NK) cell therapies with enhanced anti-tumor function —
— Lead product candidate WU-NK-101 demonstrated potent anti-tumor activity and long-term persistence in vivo —
— Data support ongoing clinical development of WU-NK-101 as best-in-class memory NK cell therapy for liquid and solid tumors —
Excerpt from the Press Release:
ST. LOUIS & SAN DIEGO–(BUSINESS WIRE)–Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today presented new data from its best-in-class memory natural killer (NK) cell therapy platform at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting. The presentation highlighted the preclinical development and proprietary manufacturing details of Wugen’s lead product candidate WU-NK-101 for the treatment of relapsed/refractory (r/r) acute myeloid leukemia (AML). The findings presented at SITC support development of WU-NK-101 as an off-the-shelf therapy for r/r AML and solid tumor indications.
“These data showcase our differentiated approach to off-the-shelf cell therapies for cancer,” said Dan Kemp, Ph.D., President and Chief Executive Officer of Wugen. “Our memory NK cell platform is uniquely designed to overcome the limitations of existing cell therapy alternatives by delivering enhanced function, persistence, and ultimately efficacy without the need for feeder cells during the manufacturing process. Eliminating this step simplifies the process and allows us to deliver a safer product. We have prioritized manufacturing from the start and are proud that today’s data underscores our preparedness to deliver our product at-scale and provide powerful treatments to patients.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?